VAG
REGN icon

VisionPoint Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

VisionPoint Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-383
Closed -$201K – 408
2025
Q2 		$201K Buy
+383
New +$214K 0.04% 351
2021
Q2 		– Sell
-600
Closed -$284K – 113
2021
Q1 		$284K Buy
+600
New +$292K 0.14% 96

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VisionPoint Advisory Group's REGN Position: Q3 2025 in Review

VisionPoint Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 383 shares — an estimated $201K sold.

VisionPoint Advisory Group first reported a position in REGN in Q1 2021 and held it in 2 quarters. The position peaked at $284K in Q1 2021. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • VisionPoint Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • VisionPoint Advisory Group sold 383 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $201K.
  • VisionPoint Advisory Group first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • VisionPoint Advisory Group's Regeneron Pharmaceuticals position peaked at $284K in Q1 2021.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on VisionPoint Advisory Group's 13F filing for Q3 2025, filed 8 Oct 2025.